Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle
| Autor: | Lilia M. Jimenez-Ceja, Rodolfo Guardado-Mendoza, Diana Farfán-Vázquez, Franco Folli, María Lola Evia-Viscarra, María Luisa Montes de Oca-Loyola, Jessica Noemí González-Mena, Yosceline Estrella Martínez-López, Alberto Aguilar-García, Katya Vargas-Ortiz, Sara Stephania Salazar-López, Mildred Fátima de la Luz Alvarez-Canales |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
endocrine system diseases medicine.medical_treatment 030204 cardiovascular system & hematology Gastroenterology law.invention Impaired glucose tolerance 0302 clinical medicine Endocrinology Randomized controlled trial law Insulin-Secreting Cells Insulin Prediabetes Multidisciplinary Endocrine system and metabolic diseases Middle Aged Metformin Medicine Drug Therapy Combination Female Pre-diabetes medicine.drug medicine.medical_specialty Science 030209 endocrinology & metabolism Linagliptin Article Prediabetic State 03 medical and health sciences Double-Blind Method Internal medicine medicine Humans Hypoglycemic Agents Life Style business.industry nutritional and metabolic diseases Glucose Tolerance Test medicine.disease Glucose Basal (medicine) Insulin Resistance business Body mass index |
| Zdroj: | Scientific Reports Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021) |
| ISSN: | 2045-2322 |
| Popis: | The goal of the study was to evaluate the effect of adding linagliptin to metformin and lifestyle on glucose levels and pancreatic β-cell function in patients with persistent impaired glucose tolerance (IGT) after 12 months of metformin and lifestyle. A single center parallel double-blind randomized clinical trial with 6 months of follow-up was performed in patients with persistent IGT after 12 months of treatment with metformin and lifestyle; patients were randomized to continue with metformin 850 mg twice daily (M group, n = 12) or linagliptin/metformin 2.5/850 mg twice daily (LM group, n = 19). Anthropometric measurements were obtained by standard methods and by bioelectrical impedance; glucose was measured by dry chemistry, insulin by chemiluminescence, and pancreatic β-cell function was calculated with the disposition index using glucose and insulin values during oral glucose tolerance test (OGTT) and adjusting by insulin sensitivity. The main outcomes were glucose levels during OGTT and pancreatic β-cell function. Patients in the LM group had a reduction in weight (−1.7 ± 0.6, p 0_120min) as compared to the M group (−4425 ± 871 vs −1116 ± 1104 mg/dl/120 min, p 0_120min. The addition of linagliptin to patients with persistent IGT after 12 months of treatment with metformin and lifestyle, improved glucose levels during OGTT and pancreatic β-cell function after 6 months of treatment.Trial registration: Clinicaltrials.gov with the ID number NCT04088461 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|